Advertisement

Heart Failure Reviews

, Volume 18, Issue 6, pp 733–746 | Cite as

Idiopathic giant cell myocarditis and cardiac sarcoidosis

  • Lori A. BlauwetEmail author
  • Leslie T. Cooper
Article

Abstract

Idiopathic giant cell myocarditis (GCM) and cardiac sarcoidosis (CS) are rare disorders that cause cardiomyopathy, often with ventricular arrhythmias or heart block. Infection, autoimmune processes, and genetics have all been implicated in the pathogenesis of these diseases, but the etiology for both diseases is likely a complex multifactorial process. Both GCM and CS are generally progressive despite treatment with standard heart failure and arrhythmia therapies. Making the diagnosis of GCM or CS on initial clinical presentation is possible in only a small percentage of patients, so myocardial tissue diagnosis is required. The use of multiple noninvasive imaging modalities may aid in diagnosis and assessment of response to treatment. Establishing the diagnosis of GCM or CS early is crucial, as tailored immunosuppressive treatment may significantly alter the clinical course of these patients. The prognosis of patients with GCM is poor, while the prognosis for patients with CS varies according to degree of left ventricular dysfunction.

Keywords

Myocarditis Sarcoidosis Dilated cardiomyopathy Endomyocardial biopsy Heart failure 

References

  1. 1.
    Cooper LT Jr (2005) Giant cell and granulomatous myocarditis. Heart Fail Clin 1:431–437PubMedGoogle Scholar
  2. 2.
    Saltykow S (1905) Uber diffuse Myokarditis. Virchows Archiv fur Pathologische Anatomie 182:1–39Google Scholar
  3. 3.
    Bernstein M, Konzelmann F, Sidlick D (1929) Boeck’s Sarcoid: report of a case with visceral involvement. Ann Int Med 44:721–734Google Scholar
  4. 4.
    Palmer H, Michael I (1965) Giant-cell myocarditis with multiple organ involvement. Arch Intern Med 116:444–447PubMedGoogle Scholar
  5. 5.
    Tesluk H (1956) Giant cell versus granulomatous myocarditis. Am J Clin Pathol 26:1326PubMedGoogle Scholar
  6. 6.
    Whitehead R (1965) Isolated myocarditis. Brit Heart J 27:220–230PubMedGoogle Scholar
  7. 7.
    Okada R, Wakafuji S (1985) Myocarditis in autopsy. Heart Vessels Suppl 1:23–29PubMedGoogle Scholar
  8. 8.
    Bresnitz EA, Strom BL (1983) Epidemiology of sarcoidosis. Epidemiol Rev 5:124–156PubMedGoogle Scholar
  9. 9.
    Hillerdal G, Nou E, Osterman K, Schmekel B (1984) Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 130:29–32PubMedGoogle Scholar
  10. 10.
    Rybicki B, Major M, Popovitch YJ, Maliarik M, Iannuzzi M (1997) Racial differences in sarcoidosis incidence: a five year study in a health maintenance organization. Am J Epidemiol 145:234–241PubMedGoogle Scholar
  11. 11.
    Johns C, Schonfeld S, Scott P, Zachary J, MacGregor M (1986) Longitudinal study of chronic sarcoidosis with low-dose maintenence corticosteroid therapy: outcome and complications. Ann NY Acad Sci 465:702–712PubMedGoogle Scholar
  12. 12.
    Roberts W, McAllister H, Ferrans V (1977) Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 63:86–108PubMedGoogle Scholar
  13. 13.
    Okura Y, Dec GW, Hare JM et al (2003) A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41:322–329PubMedGoogle Scholar
  14. 14.
    Patel AR, Klein MR, Chandra S et al (2011) Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail 13:1231–1237PubMedGoogle Scholar
  15. 15.
    Patel MR, Cawley PJ, Heitner JF et al (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120:1969–1977PubMedGoogle Scholar
  16. 16.
    Uemura A, Morimoto S, Hiramitsu S et al (1999) Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 138:299–302PubMedGoogle Scholar
  17. 17.
    Yazaki Y, Isobe M, Hiramitsu S et al (1998) Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 82:537–540PubMedGoogle Scholar
  18. 18.
    Chapelon-Abric C, de Zuttere D, Duhaut P et al (2004) Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 83:315–334Google Scholar
  19. 19.
    Smedema JP, Snoep G, van Kroonenburgh MP et al (2005) Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128:30–35PubMedGoogle Scholar
  20. 20.
    Yazaki Y, Isobe M, Hiroe M et al (2001) Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88:1006–1010PubMedGoogle Scholar
  21. 21.
    Drut RM, Drut R (1986) Giant-cell myocarditis in a newborn with congenital herpes simplex virus (HSV) infection: an immunohistochemical study on the origin of the giant cells. Pediatr Pathol 6:431–437PubMedGoogle Scholar
  22. 22.
    Meyer T, Grumbach IM, Kreuzer H, Morguet AJ (1997) Giant cell myocarditis due to coxsackie B2 virus infection. Cardiology 88:296–299PubMedGoogle Scholar
  23. 23.
    Dennert R, Schalla S, Suylen RJ, Eurlings L, Heymans S (2009) Giant cell myocarditis triggered by a parvovirus B19 infection. Int J Cardiol 134:115–116PubMedGoogle Scholar
  24. 24.
    Mascaro-Blanco A, Alvarez K, Yu X et al (2008) Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity 41:442–453PubMedGoogle Scholar
  25. 25.
    Baughman RP, Lower EE, du Bois RM (2003) Sarcoidosis. Lancet 361:1111–1118PubMedGoogle Scholar
  26. 26.
    Eishi Y, Suga M, Ishige I et al (2002) Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 40:198–204PubMedGoogle Scholar
  27. 27.
    Song Z, Marzilli L, Greenlee BM et al (2005) Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 201:755–767PubMedGoogle Scholar
  28. 28.
    Dubaniewicz A (2010) Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun Rev 9:419–424PubMedGoogle Scholar
  29. 29.
    Hajizadeh R, Sato H, Carlisle J et al (2007) Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol 27:445–454PubMedGoogle Scholar
  30. 30.
    Lee YB, Lee JI, Park HJ, Cho BK, Oh ST (2011) Interferon-alpha induced sarcoidosis with cutaneous involvement along the lines of venous drainage. Ann Dermatol 23:239–241PubMedGoogle Scholar
  31. 31.
    Benzagmout M, Oudghiri B, Boujraf S, Chakour K, Chaoui ME (2010) Fatal neurosarcoidosis induced by interferon alpha treatment in chronic hepatitis C. Neurol India 58:135–136Google Scholar
  32. 32.
    Froidure A, Horsmans Y, Lefebvre C (2009) Multisystemic sarcoidosis associated with a second therapy for chronic hepatitis C. Acta Gastroenterol Belg 72:249–251PubMedGoogle Scholar
  33. 33.
    Faurie P, Broussolle C, Zoulim F, Trepo C, Seve P (2010) Sarcoidosis and hepatitis C: clinical description of 11 cases. Eur J Gastroenterol Hepatol 22:967–972PubMedGoogle Scholar
  34. 34.
    Ramos-Casals M, Munoz S, Medina F et al (2009) Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 36:1442–1448PubMedGoogle Scholar
  35. 35.
    Shioji K, Kishimoto C, Nakayama Y, Sasayama S (2000) Strain differences in rats with experimental giant cell myocarditis. Jpn Circ J 64:283–286PubMedGoogle Scholar
  36. 36.
    Kittleson M, Minhas K, Irizarry R et al (2005) Gene expression in giant cell myocarditis: altered expression of immune response genes. Int J Cardiol 102:333–340PubMedGoogle Scholar
  37. 37.
    Asimaki A, Tandri H, Duffy ER et al (2011) Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 4:743–752PubMedGoogle Scholar
  38. 38.
    Smith G, Brownell I, Sanchez M, Prystowsky S (2008) Advances in the genetics of sarcoidosis. Clin Genet 73:401–412PubMedGoogle Scholar
  39. 39.
    Martinetti M, Luisetti M, Cuccia M (2002) HLA and sarcoidosis: new pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis 19:83–95PubMedGoogle Scholar
  40. 40.
    Rossman MD, Thompson B, Frederick M et al (2003) HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 73:720–735PubMedGoogle Scholar
  41. 41.
    Grunewald J, Brynedal B, Darlington P et al (2010) Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respir Res 11:25PubMedGoogle Scholar
  42. 42.
    Sato H, Woodhead FA, Ahmad T et al (2010) Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet 19:4100–4111PubMedGoogle Scholar
  43. 43.
    Grutters JC, Sato H, Pantelidis P et al (2002) Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 165:1119–1124PubMedGoogle Scholar
  44. 44.
    Takada T, Suzuki E, Morohashi K, Gejyo F (2002) Association of single nucleotide polymorphisms in the IL-18 gene with sarcoidosis in a Japanese population. Tissue Antigens 60:36–42PubMedGoogle Scholar
  45. 45.
    Judson MA, Marchell RM, Mascelli M et al (2011) Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J Am Acad Dermatol Sep 15. [Epub ahead of print]Google Scholar
  46. 46.
    Valentonyte R, Hampe J, Huse K et al (2005) Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 37:357–364PubMedGoogle Scholar
  47. 47.
    Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC (2005) The BTNL2 gene and sarcoidosis susceptibility in African Americans and whites. Am J Hum Genet 77:491–499PubMedGoogle Scholar
  48. 48.
    Milman N, Svendsen CB, Nielsen FC, van Overeem Hansen T (2011) The BTNL2 A allele variant is frequent in Danish patients with sarcoidosis. Clin Respir J 5:105–111PubMedGoogle Scholar
  49. 49.
    Veltkamp M, Van Moorsel CH, Rijkers GT et al (2010) Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin Exp Immun 162:68–74PubMedGoogle Scholar
  50. 50.
    Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA (2003) Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 167:1225–1231PubMedGoogle Scholar
  51. 51.
    Cooper LT Jr, Berry GJ, Shabetai R (1997) Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336:1860–1866PubMedGoogle Scholar
  52. 52.
    Kandolin R, Lehtonen J, Kupari M (2011) Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 4:303–309PubMedGoogle Scholar
  53. 53.
    Cooper LT Jr, Blauwet LA (2011) When should high-grade heart block trigger a search for a treatable cardiomyopathy? Circ Arrhythm Electrophysiol 4:260–261PubMedGoogle Scholar
  54. 54.
    Ren H, Poston R, Hruban R et al (1993) Long survival with giant cell myocarditis. Modern Pathol 6:402–407Google Scholar
  55. 55.
    Davies RA, Veinot JP, Smith S et al (2002) Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant 21:674–679PubMedGoogle Scholar
  56. 56.
    Fleming HA, Bailey SM (1981) Sarcoid heart disease. J R Coll Physicians Lond 15:245–246PubMedGoogle Scholar
  57. 57.
    Sekiguchi M, Yazaki Y, Isobe M, Hiroe M (1996) Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 10:495–510PubMedGoogle Scholar
  58. 58.
    Matsumori A, Hara M, Nagai S et al (2000) Hypertrophic cardiomyopathy as a manifestation of cardiac sarcoidosis. Jpn Circ J 64:679–683PubMedGoogle Scholar
  59. 59.
    Halushka MK, Yuh DD, Russell SD (2006) Right ventricle-dominant cardiac sarcoidosis with sparing of the left ventricle. J Heart Lung Transplant 25:479–482PubMedGoogle Scholar
  60. 60.
    James RA, Pounder DJ (1982) Cardiac sarcoidosis with spontaneous rupture of the right ventricle. Forensic Sci Int 20:167–171PubMedGoogle Scholar
  61. 61.
    Zelcer AA, LeJemtel TH, Jones J, Stahl J (1987) Pericardial tamponade in sarcoidosis. Can J Cardiol 3:12–13PubMedGoogle Scholar
  62. 62.
    Matsui Y, Iwai K, Tachibana T et al (1976) Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 278:455–469PubMedGoogle Scholar
  63. 63.
    Winters SL et al (1991) Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy, and an implantable antitachycardia device. J Am Coll Cardiol 18:937–943PubMedGoogle Scholar
  64. 64.
    Aizer A, Stern EH, Gomes JA et al (2005) Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 96:276–282PubMedGoogle Scholar
  65. 65.
    Fleming HA, Bailey SM (1981) Sarcoid heart disease. J R Coll Physicians Lond 15:245–246, 249-523Google Scholar
  66. 66.
    Ratner S, Fenoglio JJ, Ursell P (1986) Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest 90:528–533PubMedGoogle Scholar
  67. 67.
    Davies MJ, Pomerance A, Teare RD (1975) Idiopathic giant cell myocarditis–a distinctive clinico-pathological entity. Br Heart J 37:192–195PubMedGoogle Scholar
  68. 68.
    Litovsky SH, Burke AP, Virmani R (1996) Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 9:1126–1134PubMedGoogle Scholar
  69. 69.
    Ardehali H, Howard D, Hariri A et al (2005) A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150:459–463PubMedGoogle Scholar
  70. 70.
    Shields RC, Tazelaar HD, Berry GJ, Cooper LT Jr (2002) The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Cardiac Fail 8:74–78Google Scholar
  71. 71.
    Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914–1931PubMedGoogle Scholar
  72. 72.
    Wu L, Cooper L (2004) Potential of the right ventricular endomyocardial biopsy to diagnose and assist in the management of congestive heart failure: insights from recent clinical trials. Congest Heart Fail 10:133–139PubMedGoogle Scholar
  73. 73.
    Holzmann M, Nicko A, Kuhl U et al (2008) Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 118:1722–1728PubMedGoogle Scholar
  74. 74.
    Kinney EL, Jackson GL, Reeves WC, Zelis R (1980) Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients. Am J Med 68:497–503PubMedGoogle Scholar
  75. 75.
    Lewin RF, Mor R, Spitzer S et al (1985) Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 110:116–122PubMedGoogle Scholar
  76. 76.
    Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliercio CP (1989) Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 63:478–482PubMedGoogle Scholar
  77. 77.
    Gibbons WJ, Levy RD, Nava S et al (1991) Subclinical cardiac dysfunction in sarcoidosis. Chest 100:44–50PubMedGoogle Scholar
  78. 78.
    Angomachalelis N, Hourzamanis A, Vamvalis C, Gavrielides A (1992) Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J 68(Suppl 1):S52–S56PubMedGoogle Scholar
  79. 79.
    Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ (1996) Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 109:62–66PubMedGoogle Scholar
  80. 80.
    Tadamura E, Yamamuro M, Kubo S et al (2005) Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 185:110–115PubMedGoogle Scholar
  81. 81.
    Vignaux O, Dhote R, Duboc D et al (2002) Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr 26:762–767PubMedGoogle Scholar
  82. 82.
    Vignaux O (2005) Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 184:249–254PubMedGoogle Scholar
  83. 83.
    Smedema JP, Snoep G, van Kroonenburgh MP et al (2005) Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45:1683–1690PubMedGoogle Scholar
  84. 84.
    Vignaux O, Dhote R, Duboc D et al (2002) Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 122:1895–1901PubMedGoogle Scholar
  85. 85.
    Doherty MJ, Kumar SK, Nicholson AA, McGivern DV (1998) Cardiac sarcoidosis: the value of magnetic resonance imaging in diagnosis and assessment of response to treatment. Respir Med 92:697–699PubMedGoogle Scholar
  86. 86.
    Kanao S, Tadamura E, Yamamuro M et al (2005) Demonstration of cardiac involvement of sarcoidosis by contrast-enhanced multislice computed tomography and delayed-enhanced magnetic resonance imaging. J Comput Assist Tomogr 29:745–748PubMedGoogle Scholar
  87. 87.
    Smedema JP, Truter R, de Klerk PA et al (2006) Cardiac sarcoidosis evaluated with gadolinium-enhanced magnetic resonance and contrast-enhanced 64-slice computed tomography. Int J Cardiol 112:261–263PubMedGoogle Scholar
  88. 88.
    Tellier P, Paycha F, Antony I et al (1988) Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 85:189–193PubMedGoogle Scholar
  89. 89.
    Fields CL, Ossorio MA, Roy TM, Denny DM, Varga DW (1990) Thallium-201 scintigraphy in the diagnosis and management of myocardial sarcoidosis. South Med J 83:339–342PubMedGoogle Scholar
  90. 90.
    Le Guludec D, Menad F, Faraggi M et al (1994) Myocardial sarcoidosis. Clinical value of technetium-99 m sestamibi tomoscintigraphy. Chest 106:1675–1682PubMedGoogle Scholar
  91. 91.
    Yamagishi H, Shirai N, Takagi M et al (2003) Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 44:1030–1036PubMedGoogle Scholar
  92. 92.
    Kaminaga T, Takeshita T, Yamauchi T, Kawamura H, Yasuda M (2004) The role of iodine-123-labeled 15-(p-iodophenyl)-3R, S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis. Int J Cardiol 94:99–103PubMedGoogle Scholar
  93. 93.
    Yokoyama I, Momomura S, Ohtake T et al (1998) Role of positron emission tomography using fluorine-18 fluoro-2-deoxyglucose in predicting improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy. Eur J Nucl Med 25:736–743PubMedGoogle Scholar
  94. 94.
    Ishimaru S, Tsujino I, Takei T et al (2005) Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26:1538–1543PubMedGoogle Scholar
  95. 95.
    Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA (2007) Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J 29:418–422PubMedGoogle Scholar
  96. 96.
    Smedema JP, Reenaers V, Geukens R (2006) Images in cardiology. Cardiac sarcoidosis in a 60 year old woman. Heart (British Cardiac Society) 92:688Google Scholar
  97. 97.
    Takeda N, Yokoyama I, Hiroi Y et al (2002) Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 105:1144–1145PubMedGoogle Scholar
  98. 98.
    Tadamura E, Yamamuro M, Kubo S et al (2006) Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 113:e771–e773PubMedGoogle Scholar
  99. 99.
    Isiguzo M, Brunken R, Tchou P, Xu M, Culver DA (2011) Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 28:50–55PubMedGoogle Scholar
  100. 100.
    Ohira H, Tsujino I, Ishimaru S et al (2008) Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35:933–941PubMedGoogle Scholar
  101. 101.
    Okumura W, Iwasaki T, Toyama T et al (2004) Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45:989–998Google Scholar
  102. 102.
    Bartlett ML, Bacharach SL, Voipio-Pulkki LM, Dilsizian V (1995) Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med 36:188–195PubMedGoogle Scholar
  103. 103.
    Gropler RJ, Siegel BA, Lee KJ et al (1990) Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 31:1749–1756PubMedGoogle Scholar
  104. 104.
    Ohira H, Tsujino I, Sato T et al (2011) Early detection of cardiac sarcoid lesions with (18)F-fluoro-2-deoxyglucose positron emission tomography. Intern Med 50:1207–1209PubMedGoogle Scholar
  105. 105.
    Mehta D, Lubitz SA, Frankel Z et al (2008) Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133:1426–1435PubMedGoogle Scholar
  106. 106.
    Ohira H, Tsujino I, Yoshinaga K (2011) (1)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 38:1773–1783PubMedGoogle Scholar
  107. 107.
    Goldberg GM (1955) Myocarditis of the giant-cell type in an infant. Am J Clin Pathol 25:510–513PubMedGoogle Scholar
  108. 108.
    Das BB, Recto M, Johnsrude C et al (2006) Cardiac transplantation for pediatric giant cell myocarditis. J Heart Lung Transplant 25:474–478PubMedGoogle Scholar
  109. 109.
    Yabe M, Ishiguro H, Yasuda Y et al (2008) Fatal giant cell myocarditis after allogeneic bone marrow transplantation. Bone Marrow Transplant 41:93–94PubMedGoogle Scholar
  110. 110.
    Lind-Ayres MR, Abramowsky C, Mahle WT (2009) Pediatric giant cell myocarditis and orbital myositis. Pediatr Cardiol 30:510–512PubMedGoogle Scholar
  111. 111.
    Weidenbach M, Springer T, Daehnert I et al (2008) Giant cell myocarditis mimicking idiopathic fascicular ventricular tachycardia. J Heart Lung Transplant 27:238–241PubMedGoogle Scholar
  112. 112.
    Cooper LT (2007) Giant cell myocarditis in children. Prog Pediatr Cardiol 24:47–49PubMedGoogle Scholar
  113. 113.
    Serwer GA, Edwards SB, Benson DW Jr, Anderson PA, Spach M (1978) Ventricular tachyarrhythmia due to cardiac sarcoidosis in a child. Pediatrics 62:322–325PubMedGoogle Scholar
  114. 114.
    Jefic D, Joel B, Good E et al (2009) Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 6:189–195PubMedGoogle Scholar
  115. 115.
    Koplan BA, Soejima K, Baughman K, Epstein LM, Stevenson WG (2006) Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 3:924–929PubMedGoogle Scholar
  116. 116.
    Epstein AE, DiMarco JP, Ellenbogen KA et al (2008) ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 51:e1–e62PubMedGoogle Scholar
  117. 117.
    Kim JS, Judson MA, Donnino R et al (2009) Cardiac sarcoidosis. Am Heart J 157:9–21PubMedGoogle Scholar
  118. 118.
    Stoica SC, Goddard M, Tsui S et al (2003) Ventricular assist surprise: giant cell myocarditis or sarcoidosis? J Thorac Cardiovasc Surg 126:2072–2074PubMedGoogle Scholar
  119. 119.
    Eid SM, Schamp D, Halushka MK, Barouch LA (2009) Resolution of giant cell myocarditis after extended ventricular assistance. Arch Pathol Lab 133:138–141Google Scholar
  120. 120.
    Marelli D, Kermani R, Bresson J et al (2003) Support with the BVS 5000 assist device during treatment of acute giant-cell myocarditis. Tex Heart Inst J 30:50–56PubMedGoogle Scholar
  121. 121.
    Brikalas E, Olson LJ, Daly RC, Cooper LT (1999) Role of ventricular assist device support as a bridge to transplantation in giant cell myocarditis (Abstract). J Heart Lung Transplant 18:31Google Scholar
  122. 122.
    Kong G, Madden B, Spyrou N et al (1991) Response of recurrent giant cell myocarditis in a transplanted heart to intensive immunosuppression. Eur Heart J 12:554–557PubMedGoogle Scholar
  123. 123.
    Zaidi AR, Zaidi A, Vaitkus PT (2007) Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 26:714–717PubMedGoogle Scholar
  124. 124.
    Oni AA, Hershberger RE, Norman DJ et al (1992) Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 11:367–369PubMedGoogle Scholar
  125. 125.
    Yager JE, Hernandez AF, Steenbergen C et al (2005) Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 24:1988–1990PubMedGoogle Scholar
  126. 126.
    Luk A, Lee A, Ahn E et al (2010) Cardiac sarcoidosis: recurrent disease in a heart transplant patient following pulmonary tuberculosis infection. Can J Cardiol 26:e273–e275PubMedGoogle Scholar
  127. 127.
    Costanzo-Nordin M, Silver M, O’Connell J, Scanlon P, Robinson J (1987) Giant cell myocarditis: dramatic hemodynamic histologic improvement with immunosuppressive therapy. Eur Heart J 76(Suppl J):271–274Google Scholar
  128. 128.
    Levy NT, Olson LJ, Weyand C et al (1998) Histologic and cytokine response to immunosuppression in giant-cell myocarditis. Ann Int Med 128:648–650PubMedGoogle Scholar
  129. 129.
    Desjardins V, Pelletier G, Leung TK, Waters D (1992) Successful treatment of severe heart failure caused by idiopathic giant cell myocarditis. Can J Cardiol 8:788–792PubMedGoogle Scholar
  130. 130.
    Kato Y, Morimoto S, Uemura A et al (2003) Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 20:133–137PubMedGoogle Scholar
  131. 131.
    Hamzeh NY, Wamboldt FS, Weinberger HD (2011) Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2011 Jul 7. [Epub ahead of print]Google Scholar
  132. 132.
    Bargout R, Kelly RF (2004) Sarcoid heart disease: clinical course and treatment. Int J Cardiol 97:173–182PubMedGoogle Scholar
  133. 133.
    Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795–802PubMedGoogle Scholar
  134. 134.
    Baughman RP, Lower EE (1990) The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 142:1268–1271PubMedGoogle Scholar
  135. 135.
    Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U (1999) Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 14:1117–1122PubMedGoogle Scholar
  136. 136.
    Zuber M, Defer G, Cesaro P, Degos JD (1992) Efficacy of cyclophosphamide in sarcoid radiculomyelitis. J Neurol Neurosurg Psychiatry 55:166–167PubMedGoogle Scholar
  137. 137.
    Zabel P, Entzian P, Dalhoff K, Schlaak M (1997) Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 155:1665–1669PubMedGoogle Scholar
  138. 138.
    Judson MA, Silvestri J, Hartung C, Byars T, Cox CE (2006) The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:51–57PubMedGoogle Scholar
  139. 139.
    Moravan M, Segal BM (2009) Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72:337–340PubMedGoogle Scholar
  140. 140.
    Mason JW, O’Connell JB, Herskowitz A et al (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333:269–275PubMedGoogle Scholar
  141. 141.
    Fairweather D, Petri MA, Coronado MJ, Cooper LT (2012) Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol 8(3):269–84.Google Scholar
  142. 142.
    Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA (2012) Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. doi: 10.1093/europace/eus316.

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Division of Cardiovascular DiseasesMayo ClinicRochesterUSA

Personalised recommendations